Leutragin Inhibits Expression of Cytokines, Including Interleukin-6, in a “Cytokine Storm” Model in C57BL/6Y Mice with Induced Acute Respiratory Distress Syndrome

This study aims to investigate effects of leutragin, an analogue of endogenous hexapeptide dynorphin 1-6, on the expression of pro-inflammatory cytokines and type I interferons in an experimental model of fatal acute respiratory distress syndrome (ARDS) in C57BL/6Y mice. The expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor (TNF-α), interferons α (IFN-α) and β (IFN-β) in the lungs was assessed by real-time PCR. The induction of ARDS using α-galactosylceramide and E. coli lipopolysaccharide led to a multifold increase in the expression of the cytokines in the lungs. The administration of leutragin in a combined mode — intramuscular injection plus inhalation — led to a statistically significant decrease in the mRNA levels of cytokines within three hours after the start of administration. The average mRNA levels of IL-6, a key cytokine in the development of severe acute respiratory syndrome, decreased by 4.7 times (p<0.01) to reach values close to those observed in intact animals. Given the crucial role of elevated IL-6 concentrations in the development of severe forms of COVID-19, the use of leutragine for suppressing “cytokine storm” syndromes may be an effective approach to the treatment of this coronavirus infection.

leutragin, acute respiratory distress syndrome, “cytokine storm”, C57BL/6Y mice, cytokines, interleukin-6, COVID-19

1. Karkischenko N.N., Karkischenko V.N., Fokin Yu.V., Kharitonov S.Yu. Nejrovizualizaciya effektov psihoaktivnyh sredstv posredstvom normalizacii elektrogramm golovnogo mozga [Neuroimaging of the Effects of Psychoactive Substances by Means of Normalization of Brain Electrograms]. Biomedicina [Journal Biomed]. 2019;15(1):12–34. (In Russian). DOI: 10.33647/20745982-15-1-12-34.

2. Pomytkin I.A., Karkischenko V.N., Fokin Yu.V., Nesterov M.S., Petrova N.V. Model’ fatal’nogo ostrogo porazheniya legkih i ostrogo respiratornogo distress-sindroma [A fatal model of acute lung injury and acute respiratory distress syndrome]. Biomedicina [Journal Biomed]. 2020;16(4):24–33. (In Russian). DOI: 10.33647/2074-5982-16-4-24-33.

3. Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomedicinskih issledovaniyah [Manual on laboratory animals and alternative models in biomedical research]. Ed. by N.N. Karkischenko, et al. Moscow: Profil’-2S Publ., 2010. 358 p. (In Russian).

4. Chen Y., Feng Z., Diao B., Wang R., Wang G., Wang C., et al. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes. MedRxiv. 2020. DOI: 10.1101/2020.03.27.20045427.

5. Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front. Immunol. 2020;1(11):827. DOI: 10.3389/fimmu.2020.00827.

6. Fazalul Rahiman S.S., Morgan M., Gray P., Shaw P.N., Cabot P.J. Dynorphin 1-17 and Its N-Terminal Biotransformation Fragments Modulate Lipopolysaccharide-Stimulated Nuclear Factor-kappa B Nuclear Translocation, Interleukin-1beta and Tumor Necrosis Factor-alpha in Differentiated THP-1 Cells. PLoS One. 2016;11(4):e0153005. DOI: 10.1371/journal.pone.0153005.

7. Gao Y.M., Xu G., Wang B., Liu B.C. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J. Intern. Med. 2020. DOI: 10.1111/joim.13144.

8. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27(6):992–1000.e3. DOI: 10.1016/j.chom.2020.04.009.

9. Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24. DOI: 10.1016/j.cytogfr.2020.05.009.

10. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020;58(7):1021–1028. DOI: 10.1515/cclm-20200369.

11. Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017;2:17023. DOI: 10.1038/sigtrans.2017.23.

12. Luo M., Liu J., Jiang W., Yue S., Liu H., Wei S. IL-6 and CD8 + T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19. JCI Insight. 2020;5(13):139024. DOI: 10.1172/jci.insight.139024.

13. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19(6):102537. DOI: 10.1016/j.autrev.2020.102537.

14. Perricone C., Triggianese P., Bartoloni E., Cafaro G., Bonifacio A.F., Bursi R., et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J. Autoimmun. 2020;111:102468. DOI: 10.1016/j.jaut.2020.102468.

15. Sin W.X., Yeong J.P., Lim T.J.F., Su I.H., Connolly J.E., Chin K.C. IRF-7 Mediates Type I IFN Responses in Endotoxin-Challenged Mice. Front. Immunol. 2020;11:640. DOI: 10.3389/fimmu.2020.00640.

16. Vabret N., Britton G.J., Gruber C., Hegde S., Kim J., Kuksin M., et al. Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52(6):910–941. DOI: 10.1016/j.immuni.2020.05.002.

17. Wang F., Nie J., Wang H., Zhao Q., Xiong Y., Deng L., et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J. Infect. Dis. 2020;221(11):1762–1769. DOI: 10.1093/infdis/jiaa150.

18. Xu B., Fan C.Y., Wang A.L., Zou Y.L., Yu Y.H., He C., et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J. Infect. 2020;81(1):e51–e60. DOI: 10.1016/j.jinf.2020.04.012.